• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Nat Rev Cardiol . Potential long-term effects of SARS-CoV-2 infection on the pulmonary vasculature: a global perspective

tetano

Editor, Senior Moderator
Nat Rev Cardiol


. 2021 Dec 6.
doi: 10.1038/s41569-021-00640-2. Online ahead of print.
Potential long-term effects of SARS-CoV-2 infection on the pulmonary vasculature: a global perspective


Sarah Halawa[SUP] 1 [/SUP], Soni S Pullamsetti[SUP] 2 3 4 [/SUP], Charles R M Bangham[SUP] 5 [/SUP], Kurt R Stenmark[SUP] 6 [/SUP], Peter Dorfmüller[SUP] 7 [/SUP], Maria G Frid[SUP] 6 [/SUP], Ghazwan Butrous[SUP] 8 [/SUP], Nick W Morrell[SUP] 9 [/SUP], Vinicio A de Jesus Perez[SUP] 10 [/SUP], David I Stuart[SUP] 11 [/SUP], Kevin O'Gallagher[SUP] 12 [/SUP], Ajay M Shah[SUP] 12 [/SUP], Yasmine Aguib[SUP] 1 13 [/SUP], Magdi H Yacoub[SUP] 14 15 16 [/SUP]



Affiliations

Abstract

The lungs are the primary target of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, with severe hypoxia being the cause of death in the most critical cases. Coronavirus disease 2019 (COVID-19) is extremely heterogeneous in terms of severity, clinical phenotype and, importantly, global distribution. Although the majority of affected patients recover from the acute infection, many continue to suffer from late sequelae affecting various organs, including the lungs. The role of the pulmonary vascular system during the acute and chronic stages of COVID-19 has not been adequately studied. A thorough understanding of the origins and dynamic behaviour of the SARS-CoV-2 virus and the potential causes of heterogeneity in COVID-19 is essential for anticipating and treating the disease, in both the acute and the chronic stages, including the development of chronic pulmonary hypertension. Both COVID-19 and chronic pulmonary hypertension have assumed global dimensions, with potential complex interactions. In this Review, we present an update on the origins and behaviour of the SARS-CoV-2 virus and discuss the potential causes of the heterogeneity of COVID-19. In addition, we summarize the pathobiology of COVID-19, with an emphasis on the role of the pulmonary vasculature, both in the acute stage and in terms of the potential for developing chronic pulmonary hypertension. We hope that the information presented in this Review will help in the development of strategies for the prevention and treatment of the continuing COVID-19 pandemic.
 
Back
Top Bottom